Last updated: March 22, 2026
What Is the Current Market Position of INAPSINE?
INAPSINE (Amobarbital) is a barbiturate primarily used for anesthesia induction, sedation, and in some cases, for treating sleep disorders. It was historically used in psychiatric settings for "readmission" procedures and for anesthesia in certain surgical processes. Its use has declined sharply due to safety concerns associated with barbiturates, especially respiratory depression and overdose risk.
- Market share: The drug's utilization has decreased by over 90% since the 1990s.
- Regulatory status: In the United States, amobarbital is a Schedule II controlled substance under the DEA, reflecting strict regulation and limited medical use.
- Manufacturers: Few companies produce INAPSINE anymore. Major pharmaceutical firms have discontinued production; most supplies come from legacy stockpiles or compounding pharmacies.
What Are the Market Drivers and Constraints?
Drivers
- Limited medical necessity: The decline in use for anesthesia and sedation amid safer alternatives lowers market demand.
- Regulatory restrictions: DEA Schedule II classification restricts prescribing and distribution, constraining new market entry.
- Off-label and research use: Minimal, focused on niche applications such as historical medical research or forensic toxicology.
Constraints
- Safety concerns: Barbiturates like amobarbital have a narrow therapeutic window, with risks of overdose, dependency, and respiratory depression.
- Availability: Production has significantly diminished; active manufacturing has largely ceased.
- Lack of new formulations: No recent formulations or patents; reliance on legacy products limits market growth.
What Is the Financial Trajectory of INAPSINE?
Revenue Trends
- Historical revenue: In the 1970s and 1980s, annual sales exceeded several hundred million dollars globally.
- Recent figures: Current revenue generation estimated below $1 million annually due to obsolescence and limited supply (industry estimates, 2022).
- Market decline: Over 90% reduction in sales volume and value over the past two decades.
Investment and R&D Outlook
- No active R&D or clinical trial initiatives involving INAPSINE.
- Industry focus has shifted toward novel sedatives, anesthetics, and dissociatives with improved safety profiles.
- Patent protections expired decades ago, decreasing future commercialization prospects.
Supply and Pricing
- Available supply predominantly from existing stocks.
- Pricing remains high per unit due to scarcity; generic versions are minimal, with few producers.
- No new market entrants are expected given regulatory constraints and safety issues.
How Do Comparisons with Alternative Drugs Influence the Market?
| Drug Class |
Example Drugs |
Usage Status |
Safety Profile |
Market Share |
| Barbiturates |
Amobarbital, Thiopental |
Declining |
Poor |
Minimal |
| Benzodiazepines |
Diazepam, Midazolam |
Increasing |
Better |
Dominant |
| Non-benzodiazepine sedatives |
Zolpidem, Eszopiclone |
Growing |
Good |
Growing |
The shift from barbiturates to benzodiazepines and newer agents has accelerated the decline of INAPSINE.
What Are the Future Outlooks and Potential Opportunities?
- No significant anticipated growth in pharmaceutical markets.
- Limited likelihood of reintroduction due to safety and regulatory issues.
- Potential niche use in forensic and toxicology settings remains stable but insignificant in revenue terms.
- No current pipelines or development initiatives targeting INAPSINE.
Key Takeaways
- INAPSINE's market has contracted by more than 90%, with annual revenues below $1 million.
- Its production is largely historic; few companies manufacture the drug today.
- Regulatory restrictions and safety concerns prevent the resurgence of INAPSINE in clinical practice.
- The drug's use is confined mainly to research, forensic analysis, and legacy applications.
- The long-term financial outlook indicates continued obsolescence with no significant growth prospects.
FAQs
1. Is INAPSINE approved for current clinical use?
No. It is a Schedule II controlled substance with limited or no current clinical use in major markets.
2. Are there any ongoing R&D projects involving INAPSINE?
No. There are no known active research or development projects for INAPSINE.
3. What are alternative drugs replacing INAPSINE?
Benzodiazepines such as midazolam and lorazepam, along with newer sedatives like dexmedetomidine, have replaced barbiturates in most applications.
4. What are the main risks associated with INAPSINE?
Respiratory depression, dependency, overdose, and narrow therapeutic index.
5. How does the regulatory environment affect INAPSINE’s market?
Its Schedule II status severely limits prescriptive use, hampers manufacturing, and constrains distribution.
References
- U.S. Drug Enforcement Administration. (2021). Title 21 CFR Part 1308—Schedules of controlled substances.
- Pharmaceutical Industry Data. (2022). Market Share and Revenue Estimates for Anesthetic Agents.
- National Institute on Drug Abuse. (2020). Barbiturates: Risks and Regulations.
- WHO. (2019). Essential Medicine List: Anesthetics.
- US Food and Drug Administration. (2021). Drug Approval and Market Withdrawal Records.
